NCT04233229已完成不适用
Evaluation of a Closed-loop Insulin Delivery System at Home With Tailored Home Care Services in Poorly Controlled Type 2 Diabetes: a Randomized Controlled Trial vs Usual Care
Air Liquide Santé International20 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2019年12月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 20
- 主要终点
- Time in Range (TIR)
研究概览
简要总结
Closed-loop insulin delivery system has the potential to improve the condition of many poorly controlled insulin-treated Type 2 Diabetes (T2D) patients.
A wide acceptance of the Artificial Pancreas (AP) usage in T2D care will strongly depend on the identification of subpopulations and care settings where the AP could significantly improve the risk- and cost-benefit balances of T2D management as compared to established practice.
The aim of this interventional study, therefore, is to investigate whether a therapeutic solution combining an automated insulin delivery AP system with a tailored Home Healthcare Provider (HHP) service can improve blood glucose control, reduce the rate of acute metabolic complications (hypoglycaemia and hyperglycaemia), improve both the patients quality of life and experience, and reduce the healthcare related costs in patients with uncontrolled T2D needing home nursing care for their daily insulin treatment versus usual care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Selection criteria:
- •Male or female patient aged 18 years or older,
- •Type 2 Diabetes diagnosed for at least 6 months with a stable authorized antidiabetic therapeutic regimen for 3 months,
- •Treated with insulin for at least 6 months,
- •Patient with 8.0% ≤ HbA1c <12.0% within the last 3 months before selection,
- •Patient with a current minimum of 2 daily insulin injections and who would benefit of an optimisation,
- •Patient requiring long term family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring,
- •Total daily insulin dose < 1.5 U/kg,
- •Patient willing and able to complete the requirements of the study, 9.Patient living with a caregiver or a diabetes care partner, or patient living alone but with a caregiver living nearby who has a telephone and a key to his or her home, 10.Patient living in an area covered by a GSM (Global System for Mobile Communications) network and not considering a trip outside of France or out of an area covered by a GSM network within the planned dates corresponding to the 30 days of the installation of the pump (to cover the open-loop period and first 15 days of the closed-loop period), and the last 20 days of the study.
- •Inclusion Criteria:
- •Patient having demonstrated ability to understand the benefits and harms of the automated insulin delivery system and to continuously and safely wear a CGM (Continuous Glucose Monitor), as per investigator's judgement,
- •Family nurse having demonstrated ability to use the automated insulin delivery system, as per HHP judgement,
- •Patient able to use basic technology such as a cell phone and having demonstrated ability to use the automated insulin delivery system, as per Home Healthcare Provider (HHP) judgment. In case the patient has not demonstrated ability to use the automated insulin delivery system, his (her) caregiver has to demonstrate ability to use basic technology such as a cell phone and the automated insulin delivery system instead as per Home Healthcare Provider (HHP) judgment. The caregiver has to be an adult person able to speak and read French, having demonstrated ability to use the automated insulin delivery system, with no known medical condition that in the judgment of the investigator might interfere with the completion of the protocol. The caregiver must have committed to maintain uninterrupted availability via personal cell phone and to provide assistance to the patient and must be knowledgeable at all times of the participant's location during the day when closed loop is in use.
- •14 days completed (ie ≥ 70% of the daily data points non missing) CGM data from the selection period (the CGM period may be repeated only once if uncompleted data),
- •Patient covered by healthcare insurance (in accordance with French regulation),
- •Patient who has received verbal and written information about the study and who signed the informed consent form before any study related procedure.
- •Patient under curatorship must have received the agreement of their legal guardian to participate to the study.
排除标准
- •Pregnant or breastfeeding woman,
- •Patient who experienced a severe hypoglycaemic event having led to a hospitalisation or having required a third party assistance within the past 6 months,
- •Patient who experienced a diabetic ketoacidosis within the past 6 months,
- •Patient who has demonstrated a marked decrease in hypoglycaemia perception defined by a Gold score > 4,
- •Patient who has disabilities which could compromise the compliance to the study, in the investigator's opinion,
- •Patient with severe health impairment resulting in short life expectancy (< 1 year) as assessed by the investigator,
- •Patient participating in another interventional or observational clinical trial or who participated in another interventional clinical trial within 30 days before selection,
- •Patient known allergy to any component of the automated insulin delivery system compounds,
- •Proliferative retinopathy (assessed with a fundus examination or retinal photography performed within 6 months before selection or before the randomisation at the latest) with visual impairment which could compromise the safety of rapid glucose control normalisation and the compliance to the study,
- •Planned initiation of a treatment that would impact the blood glucose levels (such as steroids) during the study period,
- •Patient deprived of liberty by a judicial or administrative decision, patient admitted to a social institution or who is under a measure of legal protection, patient hospitalized without consent or who is in an emergency situation.
- •Lack of effective contraception in women of childbearing potential,
- •Subject with a history of hearing or vision impairment hindering perception of glucose display and alarms (as this point is a contra-indication stated in the user's manual of the investigational medical device),
- •Severe impairment of renal function (Creatinine Clearance < 30 mL/min),
- •Patient on dialysis (as the user's manual of Dexcom G6 states that G6 readings may be inaccurate in this population)
- •Conditions which may increase the risk of induced hypoglycemia as per the investigator's judgment,
- •lnpatient psychiatric treatment in the past 6 months,
- •Current or recent abuse of alcohol or recreational drugs,
- •Patients that have frequent exposure to magnetic resonance imaging (MRl), computed tomography (CT) scan, or high frequency electrical heat (diathermy) treatment (as this point is a contra-indication stated in the user's manual of the investigational medical device and Dexcom G6
结局指标
主要结局
Time in Range (TIR)
时间窗: From days 70 to 90
Time In Range, defined as the percentage of time spent with glucose measurements at 70-180 mg/dL (3.9-10.0 mmol/L) recorded by continuous glucose monitoring (CGM), during the last 14 days completed CGM recording from days 70 to 90
次要结局
- Time in Range (TIR) During Diurnal Period(At baseline and From days 70 to 90)
- Time in Range (TIR) During Nocturnal Period(At baseline and From days 70 to 90)
- Time Above Range (TAR) (Above 180 mg/dL)(At baseline and From days 70 to 90)
- Time Above Range (TAR) (Above 250 mg/dL)(At baseline and From days 70 to 90)
- Time Below Range (TBR) (Below 70 mg/dL)(At baseline and From days 70 to 90)
- Time Below Range (TBR) (Below 54 mg/dL)(At baseline and From days 70 to 90)
- Glucose Variability (% CV Coefficient of Variation)(At baseline and From days 70 to 90)
- HbA1c(On day 0 and day 90)
- Total Daily Insulin Dose(At selection (baseline) and study end (day 90) visits)
- Body Weight(At initiation (day 0) and study end (day 90) visits)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
不适用
Closed-loop Insulin Delivery Systems in Pancreatic DiabetesSecondary Pancreatic DiabetesNCT06227650Centre Hospitalier Sud Francilien10
已完成
不适用
A Study of t:Slim X2 With Control-IQ TechnologyType 1 Diabetes MellitusNCT03844789University of Virginia101
已完成
不适用
Clinical Assessment of a Closed-loop Insulin Delivery SystemType 1 Diabetes MellitusNCT01534013Imperial College London23
撤回
不适用
Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney TransplantDiabetes, Type 1NCT03494010Yale University
已完成
2 期
Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 DiabetesDiabetes Mellitus, Type 1NCT02814123McGill University28